# Vericiguat in Patients With Metabolic Syndrome and Coronary Vascular Dysfunction

> **NCT05711719** · PHASE2 · COMPLETED · sponsor: **Johns Hopkins University** · enrollment: 45 (actual)

## Conditions studied

- Metabolic Syndrome
- Coronary Microvascular Dysfunction

## Interventions

- **DRUG:** Vericiguat
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05711719
- **Lead sponsor:** Johns Hopkins University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-16
- **Primary completion:** 2025-11-18
- **Final completion:** 2025-11-18
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2026-01-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05711719

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05711719, "Vericiguat in Patients With Metabolic Syndrome and Coronary Vascular Dysfunction". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05711719. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*